PRESS RELEASE June 15, 2017

Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene

Immune’s subsidiary, Cytovia, plans commercialization activities in Europe and Latin America NEW YORK, June 15, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (‘Immune’) announced today that it has signed an agreement with Meda, a Mylan NV company (‘Mylan’) to repurchase assets relating to Ceplene, including the right to commercialize Ceplene in Europe and to register and commercialize Ceplene in […]

Keep Reading

NEWS April 17, 2017

BLOG: Cytovia, A Specialty Immuno-Oncology Pharmaceutical Company: From Vision Toward Implementation

Many IMNP shareholders have been asking about our vision and implementation plan for Cytovia. We now have a clear strategic business plan, validated by a leading consulting firm and by industry experts, to create a global specialty immuno-oncology pharmaceutical company around our core asset Ceplene.  As the plan is implemented, Cytovia would focus on commercialization […]

Keep Reading